1-2 of 2
David C. Myles
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination

Alison D. Parisian, Susanna A. Barratt, Leslie Hodges-Gallagher, Fabian E. Ortega, Guadalupe Peña, Judevin Sapugay, Brandon Robello, Richard Sun, David Kulp, Gopinath S. Palanisamy, David C. Myles, Peter J. Kushner, Cyrus L. Harmon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 285–300.
https://doi.org/10.1158/1535-7163.MCT-23-0351
Published: 04 March 2024
View articletitled, Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
Open the PDF for Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination in another window
Includes: Supplementary data
Journal Articles

Abstract A044: The discovery of potent KAT6 inhibitors that demonstrate anti-tumor activity in preclinical models of ER+ breast cancer

Gopinath S. Palanisamy, Chandregowda Venkateshappa, Megha Goyal, Susanna A. Barratt, Brian R. Hearn, Girish Daginakatte, Aravind A B, Samiulla D S, Kalisankar Bera, Sangeetha S, Leena Khare, Alison D. Parisian, Dirk A. Heerding, Raymond A. Ng, Cyrus L. Harmon, Susanta Samajdar, Murali Ramachandra, David C. Myles
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A044.
https://doi.org/10.1158/1535-7163.TARG-23-A044
Published: 01 December 2023
View articletitled, Abstract A044: The discovery of potent KAT6 inhibitors that demonstrate anti-tumor activity in preclinical models of ER+ breast cancer